AI powered expansion EVERSANA is actively expanding AI-powered commercialization capabilities and forming strategic partnerships with pharma players, signaling growing demand for AI-driven market access, pricing, and patient support solutions that you can align with to accelerate client engagements.

Strategic partnerships Recent partnerships with Lundbeck, Innovacell, Candel Therapeutics, and Xcovery indicate a strong channel for collaboration on U.S. launches and novel therapies, presenting opportunities to offer end-to-end commercialization services to similar biopharma clients preparing for US market entry.

Oncology focus EVERSANA highlights oncology as a key area of engagement through executive experiences and conferences; target oncology-focused biotech firms preparing for launches or access strategies to position EVERSANA as the preferred commercialization partner.

Global market access With capabilities spanning global pricing, market access, and patient support, there is a clear opportunity to target mid-sized pharma companies seeking end-to-end solutions to navigate pricing and payer landscapes across multiple regions.

Tech stack leverage The use of Power Apps, MicroStrategy, Qlik, SAP, Azure DevOps and other tools suggests potential upsell or integration opportunities around data analytics, reporting, and IT modernization for clients needing robust commercial operations platforms.